title: Direct Effects of Bevacizumab on Rat Conjunctival Fibroblast.
abstract: Successful cases of treatment of Bevacizumab for preventing scar after trabeculectomy in glaucoma patients encourage us to explore its mechanism. In this study, we primarily isolated conjunctival fibroblast from rat. RT-PCR analysis for the cells implicated that conjunctival fibroblast expressed vascular endothelial growth factor (VEGF) and its receptors. Immunofluorescence staining also showed positive staining for VEGFR-1. Furthermore, growth of fibroblast was significantly inhibited by Bevacizumab at dose of 2.5 mg/ml. Real time PCR results showed after 48 h intervention of 2.5 mg/ml Bevacizumab, the mRNA expressions of VEGF and its receptors decreased compared to the control group (P < 0.05) and Bevacizumab also decreased expression of TGFβ1 and TGFβ2 (P < 0.05). In summary, our finding demonstrated that Bevacizumab could directly act on fibroblast and inhibit VEGF, TGFβ1, and TGFβ2 expression.
authors: Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
authors: Gangwei
authors: G
authors: Cheng
authors: International Medical Center, Chinese PLA General Hospital, Beijing, China.
authors: Hang
authors: H
authors: Xiang
authors: Department of Ophthalmology, Hebei Provincial Ophthalmic Hospital, Hebei, China.
authors: Guoxing
authors: G
authors: Yang
authors: Department of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
authors: Jianmin
authors: J
authors: Ma
authors: Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. gangweic@163.com.
authors: Jialiang
authors: J
authors: Zhao
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D000068258:Bevacizumab / Q000494:pharmacology*; D002478:Cells, Cultured; D003228:Conjunctiva / Q000166:cytology*; D005347:Fibroblasts / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D053773:Transforming Growth Factor beta1 / Q000235:genetics / Q000378:metabolism; D053781:Transforming Growth Factor beta2 / Q000235:genetics / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000235:genetics / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D053773:Transforming Growth Factor beta1; D053781:Transforming Growth Factor beta2; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D040281:Vascular Endothelial Growth Factor Receptor-1
keywords: Bevacizumab; Conjunctival fibroblast; TGFβ1; TGFβ2; VEGF